TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.
choosing a selection results in a full page refresh
Product has been added to your wishlist.
You can view your wishlist by creating or login account.
Please create account through ##customer_email## email
